New 'Four-in-One' antibody takes on tough lymphoma
NCT ID NCT06066203
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called GNC-035 in 40 adults with non-Hodgkin lymphoma that has returned or not improved after standard therapy. The drug is a tetra-specific antibody designed to attack cancer cells in multiple ways. The goal is to find a safe dose and see if it can shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN'S LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Supercharged immune cells take aim at cancer and viruses in one shot
- Engineered t cells with a kill switch aim to make stem cell transplants safer
- Gut bacteria may hold key to chemo side effects
- New 'In-Body' CAR-T therapy takes aim at Hard-to-Treat lymphoma
- Experimental 'In-Situ' vaccine aims to train immune system against three cancers
- Scientists hunt for lymphoma genes in families with multiple cases